Actually, ACB's commentary kinda is an update. If accurate, sounds like manufacturing to scale has been worked through and toxicity studies are underway.
I don't think we should put any timelines on news or updates or even returning to trading. I do think it would be to the companies benefit to become more communicative as they progress through the IND enabling. They do have fiduciary duties even as a private entity to shareholders. These will become especially important IF and WHEN they achieve valuation inflection points of submitting an IND, etc.
I am thinking this could be a fabulous 2027 story... for those in the book club.
Market Data 
Markets 
